Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Pediatr Blood Cancer 2020 01;67(1):e28021

Date

10/02/2019

Pubmed ID

31571395

DOI

10.1002/pbc.28021

Scopus ID

2-s2.0-85073970426   1 Citation

Abstract

Hypersensitivity to pegaspargase is associated with inferior survival in pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. In the past year, drug-supply shortages have led to the lack of an available alternative to pegaspargase. Rather than omit asparaginase from the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma patients with hypersensitivity to pegaspargase, we continued pegaspargase treatments for nine pediatric patients, utilizing a rapid desensitization protocol. There were no adverse events related to the pegaspargase during desensitization, and all patients who were checked had asparaginase serum levels above the threshold of 0.1 IU/mL at 7 to 14 days after pegaspargase therapy.

Author List

August KJ, Farooki S, Fulbright JM, August A, Portnoy JM, Pommert L, Burke MJ, Guest EM

Author

Michael James Burke MD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Antineoplastic Agents
Asparaginase
Desensitization, Immunologic
Humans
Lymphoma, T-Cell
Male
Polyethylene Glycols
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognosis
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a